文献速递眼底病与葡萄膜炎

一种新型可生物降解地塞米松植入剂(AR-1105)治疗视网膜中央或分支静脉阻塞所致黄斑水肿的2期随机研究(ORION-1)

PHASE 2 RANDOMIZED STUDY (ORION-1) OF A NOVEL, BIODEGRADABLE DEXAMETHASONE IMPLANT (AR-1105) FOR THE TREATMENT OF MACULAR EDEMA DUE TO CENTRAL OR BRANCH RETINAL VEIN OCCLUSION.
PubMed 文献 · Retina · 2022-10-14

ORION-1为2期随机研究,评估两种释放特性的AR-1105地塞米松植入剂(单次玻璃体内注射340微克)治疗视网膜静脉阻塞所致黄斑水肿。随访6个月,两种制剂均改善视力并减轻视网膜增厚,最常见不良事件为视力下降、黄斑水肿加重、结膜下出血和眼压升高,无患者因眼压控制需手术或激光。

要点

  • 第6个月时,CF1组和CF2组最佳矫正视力平均分别变化+4.3和+8.0个字母。
  • 第6个月时,CF1组和CF2组中央亚field厚度平均分别变化-93微米和-211微米。
  • 两种制剂均耐受良好,未报告因眼压控制需手术或激光的患者。

核心结论

  • 两种AR-1105制剂均耐受良好,并在长期黄斑水肿的视网膜静脉阻塞患者中显示出有临床意义且持续的视力和视网膜增厚改善。

研究设计与样本

  • 2期研究,初始阶段5例患者接受临床制剂(CF)1,随机阶段44例患者按1:1随机分配至CF1或CF2,随访6个月。
  • 患者接受单次玻璃体内注射340微克地塞米松,入组者为筛查前≥9个月(视网膜中央静脉阻塞)或≥12个月(视网膜分支静脉阻塞)诊断的黄斑水肿所致视力丧失者,可初治或经治(若既往接受过类固醇必须显示应答)。

主要发现

  • 两种制剂在所有访视中均较基线改善视力并减轻视网膜增厚。
  • 第6个月时,CF1组和CF2组最佳矫正视力平均分别变化+4.3和+8.0个字母。
  • 第6个月时,CF1组和CF2组中央亚field厚度平均分别变化-93微米和-211微米。
  • 最常见不良事件为视力下降、黄斑水肿加重、结膜下出血和眼压升高。
  • 无患者因眼压控制需要手术或激光。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: AR-1105 is a novel biodegradable sustained-release dexamethasone implant designed to deliver 6-month durability. This Phase 2 study evaluated two AR-1105 formulations with different release profiles in patients with macular edema due to retinal vein occlusion. METHODS: Patients received a single intravitreal injection with 340 µg dexamethasone. In the initial phase, five patients received clinical formulation (CF) 1. In the randomized phase, 44 patients were randomized 1:1 to CF1 or CF2. The follow-up was 6 months. Patients had vision loss due to macular edema diagnosed ≥9 (central retinal vein occlusion) or ≥12 months (branch retinal vein occlusion) before screening, and could be treatment-naive or -experienced (if received prior steroids, must have demonstrated response). RESULTS: Both formulations improved vision and reduced retinal thickening from baseline across all visits. At Month 6, mean changes in best-corrected visual acuity were +4.3 and +8.0 letters, and mean changes in central subfield thickness were -93 µm and -211 µm in CF1 and CF2 randomized patients, respectively. Most common adverse events were reduced visual acuity, worsening macular edema, conjunctival hemorrhage, and increased intraocular pressure. No patients required surgery or laser for intraocular pressure control. CONCLUSION: Both formulations were well tolerated and demonstrated clinically meaningful and sustained improvements in vision and retinal thickening in patients with retinal vein occlusion with longstanding edema.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Singer MA, Boyer DS, Williams S, et al. PHASE 2 RANDOMIZED STUDY (ORION-1) OF A NOVEL, BIODEGRADABLE DEXAMETHASONE IMPLANT (AR-1105) FOR THE TREATMENT OF MACULAR EDEMA DUE TO CENTRAL OR BRANCH RETINAL VEIN OCCLUSION. Retina. 2022. PMID: 36542081. doi:10.1097/IAE.0000000000003632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。